Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Herc who wrote (3522)	7/30/1999 8:44:00 PM
From: Robohogs	Respond to of 10280

This is a company with over a dozen products under development and which will rapidly come to market over the next 5 years. Current revenues of drugs which SEPR drugs will replace are in the $10 billion range and SEPR will receive royalties on the drugs which they have licensed. This thing will earn in the $20 range by the mid 2000s. Given Genentech at 100x and IMNX at over 100x, let's see, could we see a $2,000 share price in the next five years? I say yes.

To: Herc who wrote (3522)	7/30/1999 10:03:00 PM
From: BMcV	Read Replies (1) \| Respond to of 10280

One problem is that your comparables are in a different business. SEPR is not a process/platform company, though it was, historically, and still has some ambitions in that area. That is not a great business, given the intense competition and the limited markets for high throughput screening machines and so forth. In contrast, SEPR's potential markets are huge and ubiquitous: allergies, asthma, heart-burn, depression. They have several candidates in each of those areas, any one of which could turn into a blockbuster. Take a look at Immunex, or the $4 billion J&J just shelled out for Centocor, to get an idea what one big drug is worth. >>Are you all in love with the stock?<< At this point, I'd say it's more a love/hate thing.